[Pergolide: a useful agonist for the treatment of Parkinson disease].
The efficiency of pergolide has been confirmed by the study of a group 29 parkinsonian patients. They were relatively young, and the duration of evolution of their Parkinson's disease was more then ten years, with levodopa-induced dyskinesia and fluctuations. In this group of patients with most serious motor disability, it has been possible to improve dyskinesia and fluctuations with a relatively important dosage of pergolide and without increase of levodopa dosage.
Bonnet
A M
AM
Fédération de Neurologie, INSERM U289, Hôpital Pitié-Salpêtrière, 47 Bd de L'Hôpital, 75651 Paris.
Houeto
J L
JL
D000978:Antiparkinson Agents / Q000009:adverse effects / Q000627:therapeutic use*; D018450:Disease Progression; D018491:Dopamine Agonists / Q000009:adverse effects / Q000627:therapeutic use*; D004409:Dyskinesia, Drug-Induced / Q000503:physiopathology; D004599:Electric Stimulation Therapy; D005260:Female; D006801:Humans; D007980:Levodopa / Q000009:adverse effects / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D010300:Parkinson Disease / Q000188:drug therapy*; D010479:Pergolide / Q000009:adverse effects / Q000627:therapeutic use*
D000978:Antiparkinson Agents; D018491:Dopamine Agonists; D010479:Pergolide; D007980:Levodopa